Robert Norman Harden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Robert Norman Harden has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Goebel
Pain Research Institute, University of Liverpool, Liverpool, United Kingdom
3 shared publications - Stephen Bruehl
Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, USA
3 shared publications - Christian Maihöfner
Klinikum Fürth
2 shared publications - Florian Brunner
Physical Medicine and Rheumatology, Balgrist University Hospital, University of Zurich, Zurich, Switzerland
2 shared publications - Frank Birklein
Department of Neurology, University Medical Centre Mainz, Mainz, Germany
2 shared publications - Lone F. Knudsen
National Rehabilitation Center for Neuromuscular Diseases, Aarhus, Denmark
2 shared publications
Latest Publications
- 27 August 2026
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (10) , 2464-2465
Reply to Alcántara Montero: the definition of regional pain should be agnostic to potential underlying mechanisms
Was not provided for this article.
- 27 August 2026
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (10) , 2464-2465
Reply to Alcántara Montero: the definition of regional pain should be agnostic to potential underlying mechanisms
Was not provided for this article.
- Open Access
- 3 April 2026
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 11 (3) , e1410
Validation of a self-report measure for diagnostic screening and assessment in complex regional pain syndrome
Introduction: Complex regional pain syndrome (CRPS) is an orphan condition with no interventions proven effective in large-scale clinical trials. In-person clinical evaluations are required to make a CRPS diagnosis and determine study eligibility, making recruitment for CRPS trials challenging. Objectives: We developed and validated a self-report measure of CRPS symptoms suitable for remote administration. Methods: We evaluated diagnostic accuracy of a self-report version of the CRPS Severity Score (CSS-SR) and assessed its validity relative to the original clinician-completed CSS (CSS-Clinician) in two samples: 112 postsurgical patients with total knee arthroplasty and 80 patients with CRPS and non-CRPS limb pain attending a chronic pain clinic. All patients completed the CSS-SR and underwent a semi-structured history and physical examination from which the CSS-Clinician was scored and a criterion-based Budapest CRPS diagnosis was determined. Results: There was good to excellent correspondence (intraclass correlations [ICCs]) between CSS-Clinician and CSS-SR total scores (postsurgical sample: ICCs = 0.86-0.92; pain clinic sample: ICC = 0.76). In the postsurgical sample, the 2 measures displayed good agreement regarding changes in CRPS features across 2 assessments 4 months apart (ICC = 0.84). The CSS-SR exhibited high diagnostic accuracy in receiver operating characteristic analyses (area under the curve = 0.84–0.94). In the pain clinic sample, a CSS-SR cutoff of ≥8 had a 79% probability of correctly predicting a Budapest CRPS diagnosis after full evaluation (sensitivity = 0.79, specificity = 0.79). Conclusion: The CSS-SR appears valid as a self-report measure of CRPS status and displays good accuracy as a remote diagnostic screening tool.
- 3 April 2026
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 11 (3) , e1410
Open AccessValidation of a self-report measure for diagnostic screening and assessment in complex regional pain syndrome
Introduction: Complex regional pain syndrome (CRPS) is an orphan condition with no interventions proven effective in large-scale clinical trials. In-person clinical evaluations are required to make a CRPS diagnosis and determine study eligibility, making recruitment for CRPS trials challenging. Objectives: We developed and validated a self-report measure of CRPS symptoms suitable for remote administration. Methods: We evaluated diagnostic accuracy of a self-report version of the CRPS Severity Score (CSS-SR) and assessed its validity relative to the original clinician-completed CSS (CSS-Clinician) in two samples: 112 postsurgical patients with total knee arthroplasty and 80 patients with CRPS and non-CRPS limb pain attending a chronic pain clinic. All patients completed the CSS-SR and underwent a semi-structured history and physical examination from which the CSS-Clinician was scored and a criterion-based Budapest CRPS diagnosis was determined. Results: There was good to excellent correspondence (intraclass correlations [ICCs]) between CSS-Clinician and CSS-SR total scores (postsurgical sample: ICCs = 0.86-0.92; pain clinic sample: ICC = 0.76). In the postsurgical sample, the 2 measures displayed good agreement regarding changes in CRPS features across 2 assessments 4 months apart (ICC = 0.84). The CSS-SR exhibited high diagnostic accuracy in receiver operating characteristic analyses (area under the curve = 0.84–0.94). In the pain clinic sample, a CSS-SR cutoff of ≥8 had a 79% probability of correctly predicting a Budapest CRPS diagnosis after full evaluation (sensitivity = 0.79, specificity = 0.79). Conclusion: The CSS-SR appears valid as a self-report measure of CRPS status and displays good accuracy as a remote diagnostic screening tool.
- Open Access
- 15 November 2023
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 8 (6) , e1111
Subtypes of complex regional pain syndrome—a systematic review of the literature
To systematically identify and summarize possible subtypes of complex regional pain syndrome (CRPS), we searched MEDLINE, Embase, Cochrane, Scopus, and Web of Science for original studies reporting or investigating at least one subtype within a group of patients with CRPS. The search retrieved 4239 potentially relevant references. Twenty-five studies met our inclusion criteria and were included in the analysis. Complex regional pain syndrome phenotypes were investigated based on the following variables: clinical presentation/sensory disturbances, dystonia, skin temperature, disease duration, onset type, CRPS outcome, and neuropsychological test performance. Support was found for the following CRPS subtypes: CRPS type I, CRPS type II, acute CRPS, chronic CRPS, centralized CRPS, cold CRPS, warm CRPS, inflammatory CRPS, dystonic CRPS, nondystonic CRPS, familial CRPS, and nonfamilial CRPS. It is unclear whether these are distinct or overlapping subtypes. The results of this comprehensive review can facilitate the formulation of well-defined CRPS subtypes based on presumed underlying mechanisms. Our findings provide a foundation for establishing and defining clinically meaningful CRPS subtypes, with the ultimate goal of developing targeted and enhanced treatments for CRPS.
- 15 November 2023
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 8 (6) , e1111
Open AccessSubtypes of complex regional pain syndrome—a systematic review of the literature
To systematically identify and summarize possible subtypes of complex regional pain syndrome (CRPS), we searched MEDLINE, Embase, Cochrane, Scopus, and Web of Science for original studies reporting or investigating at least one subtype within a group of patients with CRPS. The search retrieved 4239 potentially relevant references. Twenty-five studies met our inclusion criteria and were included in the analysis. Complex regional pain syndrome phenotypes were investigated based on the following variables: clinical presentation/sensory disturbances, dystonia, skin temperature, disease duration, onset type, CRPS outcome, and neuropsychological test performance. Support was found for the following CRPS subtypes: CRPS type I, CRPS type II, acute CRPS, chronic CRPS, centralized CRPS, cold CRPS, warm CRPS, inflammatory CRPS, dystonic CRPS, nondystonic CRPS, familial CRPS, and nonfamilial CRPS. It is unclear whether these are distinct or overlapping subtypes. The results of this comprehensive review can facilitate the formulation of well-defined CRPS subtypes based on presumed underlying mechanisms. Our findings provide a foundation for establishing and defining clinically meaningful CRPS subtypes, with the ultimate goal of developing targeted and enhanced treatments for CRPS.
- Open Access
- 12 October 2023
- Published by Elsevier in The Journal of Pain
- Vol. 25 (2) , 508-521
The Medication Quantification Scale 4.0: An Updated Index Based on Prescribers' Perceptions of the Risk Associated With Chronic Pain Medications
- 12 October 2023
- Published by Elsevier in The Journal of Pain
- Vol. 25 (2) , 508-521
Open AccessThe Medication Quantification Scale 4.0: An Updated Index Based on Prescribers' Perceptions of the Risk Associated With Chronic Pain Medications
- 1 August 2022
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 23 (8) , 1466-1467
In Memoriam: Dr. Jeffrey Fudin
Our dear friend and colleague Jeffrey Fudin passed away on Friday, May 27, 2022, at age 63. Jeff grew up in Newburgh, New York, and graduated from Newburgh Free Academy and later from the Albany College of Pharmacy, Albany, New York, for his undergraduate degree and doctorate in pharmacy. During this time, he met his partner for life, Robin, and is survived by her and by his father, Gilbert Fudin; his siblings, Terry Fudin and Debbie Radowitz; his four children, Jason Fudin, Sarah Hermalyn, Hannah Fudin, and Shirah Bettinger, and their spouses; and his seven beloved grandchildren, Jonah Fudin, Anna Hermalyn, Aria Bettinger, Penny Fudin, Emily Hermalyn, Asher Bettinger, and Jethro Colley. Dr. Fudin is also survived by his bereaved friends, colleagues, and students. He had very important roles in many of our lives as friend, colleague, fabulous teacher, thorough mentor, wry wit, and an amazing font of pharmacological knowledge...
- 1 August 2022
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 23 (8) , 1466-1467
In Memoriam: Dr. Jeffrey Fudin
Our dear friend and colleague Jeffrey Fudin passed away on Friday, May 27, 2022, at age 63. Jeff grew up in Newburgh, New York, and graduated from Newburgh Free Academy and later from the Albany College of Pharmacy, Albany, New York, for his undergraduate degree and doctorate in pharmacy. During this time, he met his partner for life, Robin, and is survived by her and by his father, Gilbert Fudin; his siblings, Terry Fudin and Debbie Radowitz; his four children, Jason Fudin, Sarah Hermalyn, Hannah Fudin, and Shirah Bettinger, and their spouses; and his seven beloved grandchildren, Jonah Fudin, Anna Hermalyn, Aria Bettinger, Penny Fudin, Emily Hermalyn, Asher Bettinger, and Jethro Colley. Dr. Fudin is also survived by his bereaved friends, colleagues, and students. He had very important roles in many of our lives as friend, colleague, fabulous teacher, thorough mentor, wry wit, and an amazing font of pharmacological knowledge...
- Top Cited PapersOpen Access
- 10 June 2022
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 23 (Supplement) , S1-S53
Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 5th Edition
There have been some modest recent advancements in the research of Complex Regional Pain Syndrome, yet the amount and quality of the work in this complicated multifactorial disease remains low (with some notable exceptions; e.g., the recent work on the dorsal root ganglion stimulation). The semi-systematic (though in some cases narrative) approach to review is necessary so that we might treat our patients while waiting for “better research.” This semi-systematic review was conducted by experts in the field, (deliberately) some of whom are promising young researchers supplemented by the experience of “elder statesman” researchers, who all mention the system they have used to examine the literature. What we found is generally low- to medium-quality research with small numbers of subjects; however, there are some recent exceptions to this. The primary reason for this paucity of research is the fact that this is a rare disease, and it is very difficult to acquire a sufficient sample size for statistical significance using traditional statistical approaches. Several larger trials have failed, probably due to using the broad general diagnostic criteria (the “Budapest” criteria) in a multifactorial/multi-mechanism disease. Responsive subsets can often be identified in these larger trials, but not sufficient to achieve statistically significant results in the general diagnostic grouping. This being the case the authors have necessarily included data from less compelling protocols, including trials such as case series and even in some instances case reports/empirical information. In the humanitarian spirit of treating our often desperate patients with this rare syndrome, without great evidence, we must take what data we can find (as in this work) and tailor a treatment regime for each patient.
- 10 June 2022
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 23 (Supplement) , S1-S53
Top Cited PapersOpen AccessComplex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 5th Edition
There have been some modest recent advancements in the research of Complex Regional Pain Syndrome, yet the amount and quality of the work in this complicated multifactorial disease remains low (with some notable exceptions; e.g., the recent work on the dorsal root ganglion stimulation). The semi-systematic (though in some cases narrative) approach to review is necessary so that we might treat our patients while waiting for “better research.” This semi-systematic review was conducted by experts in the field, (deliberately) some of whom are promising young researchers supplemented by the experience of “elder statesman” researchers, who all mention the system they have used to examine the literature. What we found is generally low- to medium-quality research with small numbers of subjects; however, there are some recent exceptions to this. The primary reason for this paucity of research is the fact that this is a rare disease, and it is very difficult to acquire a sufficient sample size for statistical significance using traditional statistical approaches. Several larger trials have failed, probably due to using the broad general diagnostic criteria (the “Budapest” criteria) in a multifactorial/multi-mechanism disease. Responsive subsets can often be identified in these larger trials, but not sufficient to achieve statistically significant results in the general diagnostic grouping. This being the case the authors have necessarily included data from less compelling protocols, including trials such as case series and even in some instances case reports/empirical information. In the humanitarian spirit of treating our often desperate patients with this rare syndrome, without great evidence, we must take what data we can find (as in this work) and tailor a treatment regime for each patient.
- Top Cited PapersOpen Access
- 15 March 2021
- Published by Wolters Kluwer Health in Pain
- Vol. 162 (9) , 2346-2348
The Valencia consensus-based adaptation of the IASP complex regional pain syndrome diagnostic criteria
An abstract is unavailable. This article is available as a PDF only.
- 15 March 2021
- Published by Wolters Kluwer Health in Pain
- Vol. 162 (9) , 2346-2348
Top Cited PapersOpen AccessThe Valencia consensus-based adaptation of the IASP complex regional pain syndrome diagnostic criteria
An abstract is unavailable. This article is available as a PDF only.
- 18 February 2016
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 17 (12) , 2305-2310
“Managing” the Placebo Effect: The Single-Blind Placebo Lead-in Response in Two Pain Models
Objective. “Placebo effects” in analgesic medication trials for chronic pain are pervasive; however, little is known regarding mechanisms or factors that may influence the presence or magnitude of these effects. Our objective is to consider elements of the placebo response in the context of two pain models using a “single-blind placebo lead-in” design (SBPLI). Methods. As part of two pilot drug trials using knee osteoarthritis (KOA) and non-radicular low back pain (LBP) subjects, SBPLI protocols were conducted. We examined whether gender and/or diagnosis affected placebo responses as observed in changes in patient self-reported pain, depressive and pain anxiety symptoms. We also evaluated the placebo response on performance-based tests (stair climbing, range of motion (ROM), sit to stand repetitions, and 6-minute treadmill distance). Results. VAS Pain Intensity (Now) values decreased significantly during the SBPLI for the sample as a whole, but the effects appeared stronger among LBP subjects. CES-D short form values (depressive symptoms) did not decrease significantly during the SBPLI for the sample as a whole, but some placebo effects appeared to emerge for women in the KOA group. PASS values (pain anxiety symptoms) decreased significantly, albeit mildly, during the SBPLI for the sample as a whole. Stair Climb (time) revealed no significant SBPLI effects. Bend Forward to Floor (ROM) increased significantly at the end of the SBPLI period for the sample as a whole, but the effects appeared stronger among KOA subjects. Sit to Stand Repetitions increased during the SBPLI for the sample as a whole. Treadmill Distance did not change significantly from Visit 1 to Visit 2; however, a significant Sex difference for the KOA group was found such that women showed greater Treadmill Distance at Visit 2. Conclusion. Placebo effects emerged across psychometric and performance-based measures, indicating the pervasiveness of this phenomenon. In this design, diagnostic and (to a lesser extent) gender categories differentials were observed during the placebo period. The SBPLI design may prove not only a robust method in studying the placebo phenomena, but also as a design element to mitigate some aspects of the placebo response in clinical trials.
- 18 February 2016
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 17 (12) , 2305-2310
“Managing” the Placebo Effect: The Single-Blind Placebo Lead-in Response in Two Pain Models
Objective. “Placebo effects” in analgesic medication trials for chronic pain are pervasive; however, little is known regarding mechanisms or factors that may influence the presence or magnitude of these effects. Our objective is to consider elements of the placebo response in the context of two pain models using a “single-blind placebo lead-in” design (SBPLI). Methods. As part of two pilot drug trials using knee osteoarthritis (KOA) and non-radicular low back pain (LBP) subjects, SBPLI protocols were conducted. We examined whether gender and/or diagnosis affected placebo responses as observed in changes in patient self-reported pain, depressive and pain anxiety symptoms. We also evaluated the placebo response on performance-based tests (stair climbing, range of motion (ROM), sit to stand repetitions, and 6-minute treadmill distance). Results. VAS Pain Intensity (Now) values decreased significantly during the SBPLI for the sample as a whole, but the effects appeared stronger among LBP subjects. CES-D short form values (depressive symptoms) did not decrease significantly during the SBPLI for the sample as a whole, but some placebo effects appeared to emerge for women in the KOA group. PASS values (pain anxiety symptoms) decreased significantly, albeit mildly, during the SBPLI for the sample as a whole. Stair Climb (time) revealed no significant SBPLI effects. Bend Forward to Floor (ROM) increased significantly at the end of the SBPLI period for the sample as a whole, but the effects appeared stronger among KOA subjects. Sit to Stand Repetitions increased during the SBPLI for the sample as a whole. Treadmill Distance did not change significantly from Visit 1 to Visit 2; however, a significant Sex difference for the KOA group was found such that women showed greater Treadmill Distance at Visit 2. Conclusion. Placebo effects emerged across psychometric and performance-based measures, indicating the pervasiveness of this phenomenon. In this design, diagnostic and (to a lesser extent) gender categories differentials were observed during the placebo period. The SBPLI design may prove not only a robust method in studying the placebo phenomena, but also as a design element to mitigate some aspects of the placebo response in clinical trials.